Literature DB >> 18625522

BAFF is up-regulated in central nervous system of neuro-Behçet's disease.

Kamel Hamzaoui1, Habib Houman, Faycal Hentati, Agnes Hamzaoui.   

Abstract

We report that B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed in central nervous system (CNS) of neuro-Behçet's disease (NBD). This study investigated BAFF and BAFF-R (BAFF receptor) in NBD, compared to multiple sclerosis (MS) and to non inflammatory neurological diseases (NIND). Cerebrospinal fluid (CSF) was used to determine the level of BAFF messenger RNA (mRNA) and the level of BAFF-R mRNA in unfractionated cells. A sandwich ELISA was used to quantify soluble BAFF protein levels in serum and in CSF. BAFF and BAFF-R expression in CSF were increased in NBD and MS patients compared to NIND patients. RNA levels of BAFF and BAFF-R were significantly correlated in NBD and MS patients. Serum sBAFF levels were increased in NBD and MS patients, but did not correlate with BAFF expression in CSF. CNS-produced BAFF may support inflammatory cell survival in NBD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18625522     DOI: 10.1016/j.jneuroim.2008.06.006

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  9 in total

Review 1.  Behçet's syndrome pathophysiology and potential therapeutic targets.

Authors:  Giacomo Emmi; Elena Silvestri; Danilo Squatrito; Mario Milco D'Elios; Lucia Ciucciarelli; Domenico Prisco; Lorenzo Emmi
Journal:  Intern Emerg Med       Date:  2014-01-12       Impact factor: 3.397

2.  Release of B cell-activating factor of the TNF family in bronchoalveolar lavage from Behçet's disease with pulmonary involvement.

Authors:  Agnès Hamzaoui; Hanene Chelbi; Fayçal Hai Sassi; Kamel Hamzaoui
Journal:  Oxid Med Cell Longev       Date:  2010 Mar-Apr       Impact factor: 6.543

3.  Cerebrospinal fluid biomarkers implicated in the pathogenesis of anti-neutrophil cytoplasmic antibody-related hypertrophic pachymeningitis.

Authors:  Junji Ikeda; Yasuhiro Shimojima; Yoko Usami; Ken-Ichi Ueno; Dai Kishida; Yoshiki Sekijima
Journal:  Clin Rheumatol       Date:  2020-02-08       Impact factor: 2.980

4.  Rapamycin Modulates the Proinflammatory Memory-Like Response of Microglia Induced by BAFF.

Authors:  Jianing Wang; Chunshu Yang; Xiaoyu Hou; Jingyi Xu; Yang Yun; Ling Qin; Pingting Yang
Journal:  Front Immunol       Date:  2021-05-12       Impact factor: 7.561

5.  Expression of TNF-α, APRIL and BCMA in Behcet's disease.

Authors:  Olfat G Shaker; Shereen O Tawfic; Amira M El-Tawdy; Mohamed H M El-Komy; Manal El Menyawi; Ahmed A Heikal
Journal:  J Immunol Res       Date:  2014-11-05       Impact factor: 4.818

Review 6.  Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents.

Authors:  Aleksander Lenert; Petar Lenert
Journal:  Drug Des Devel Ther       Date:  2015-01-07       Impact factor: 4.162

7.  CSF/serum matrix metallopeptidase-9 ratio discriminates neuro Behçet from multiple sclerosis.

Authors:  Alessandra Aldinucci; Elena Bonechi; Tiziana Biagioli; Anna M Repice; Mario M D'Elios; Lorenzo Emmi; Giacomo Emmi; Elena Silvestri; Alessandro Barilaro; Clara Ballerini
Journal:  Ann Clin Transl Neurol       Date:  2018-03-10       Impact factor: 4.511

8.  B Cells Specific CpG Induces High IL-10 and IL-6 Expression In Vitro in Neuro-Behçet's Disease.

Authors:  Olfa Maghrebi; Meriam Belghith; Cyrine Jeridi; Amine Rachdi; Fatma Nabli Fatnassi; Zakaria Saied; Samir Belal; Samia Ben Sassi; Mohamed-Ridha Barbouche
Journal:  Cells       Date:  2022-04-12       Impact factor: 7.666

9.  BAFF/APRIL system in pediatric OMS: relation to severity, neuroinflammation, and immunotherapy.

Authors:  Michael R Pranzatelli; Elizabeth D Tate; Nathan R McGee; Anna L Travelstead; Jerry A Colliver; Jayne M Ness; Richard M Ransohoff
Journal:  J Neuroinflammation       Date:  2013-01-16       Impact factor: 8.322

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.